We are a national coalition of AIDS activists, many living with HIV/AIDS,working together to end the AIDS epidemic by advancing research on HIV/AIDS

User: Password: Remember me: Forget Password?

Enter the email address of your account below to receive your password:

Gilead Sciences

Community Affairs Manager:
Cara Miller

Email: Cara.Miller@gilead.com
Phone: 650-522-1616

 

Approved Drugs:

1) Viread (tenofovir-NRTI)

2) Emtriva (FTC-NRTI)

3) Truvada (tenofovir/FTC multi-class combination)

4) Atripla (tenofovir/FTC/efavirenz multi-class combination)

5) Hespera (adefovir‒NRTI for HBV)

6) Ambisome (amphotericin B for cryptoccocal meningitis)

7) Vistide (cidofovir for CMV retinitis)

Drugs in Pre-approval Status:

1) Elvitegravir--boosted integrase inhibitor

Comment: In Phase III, much data published

2) "Quad" TDF/FTC/ELV/booster fixed dose combination

Comment: Announced in February 2009

3) GS 9350 pharmaco enhancer

Comment: Data at CROI

4) GS 9450 (caspase inhibitor for HCV/NASH)

Comment: Phase II

5) GS 9190 (polymerase inhibitor for HCV)

Comment: Phase II

Patient Assistance Program:

Telephone: 800-226-2056

Website: http://www.gilead.com/us_advancing_access

 

For Atripla: 866-290-4767

Website: http://www.bms.com/static/patient_assistance/data/atripla.html

Corporate website: www.gilead.com